Schwab Andrew J. 4

What Happened
Andrew J. Schwab, a director of Skye Bioscience (SKYE), received a grant of 35,000 stock options on February 6, 2026. The Form 4 reports the acquisition as a derivative award (transaction code A) at a reported price of $0.00 per share (total $0 as reported). This is an equity award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-06 (reported on Form 4 filed 2026-02-09).
• Security: 35,000 stock option awards; reported acquisition price $0.00 per share (derivative).
• Post-transaction holdings: Not specified in the provided filing.
• Footnote: F1 — "The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."
• Timeliness: Filed within standard Form 4 timing (filed Feb 9 for a Feb 6 transaction); not indicated as late.

Context
This was an award/grant of stock options to a board director, not an immediate sale or open-market purchase. The options vest monthly over one year beginning Jan 19, 2026; they are reported as a derivative grant and do not indicate any immediate cash transaction. As with most grants, the filing is informational about compensation and does not by itself signal insider buying or selling intent.